Total correction of hemophilia A mice with canine FVIII using an AAV 8 serotype

Blood

Volumn 103, Issue 4, 2004, Pages 1253-1260

  Sarkar, Rita ^a   Tetreault, Renee ^b   Gao, Guangping ^b   Wang, Lili ^b   Bell, Peter ^b   Chandler, Randy ^b   Wilson, James M ^b   Kazazian Jr , Haig H ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; COMPLEMENTARY DNA; HEAVY CHAIN COMPLEMENTARY DNA; LIGHT CHAIN COMPLEMENTARY DNA; RECOMBINANT BLOOD CLOTTING FACTOR 8; UNCLASSIFIED DRUG;

ADENO ASSOCIATED VIRUS; ADENO ASSOCIATED VIRUS 2; ADENO ASSOCIATED VIRUS 5; ADENO ASSOCIATED VIRUS 7; ADENO ASSOCIATED VIRUS 8; ADOLESCENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPARATIVE STUDY; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; HEMOPHILIA A; LIVER; MOUSE; NONHUMAN; PORTAL VEIN; PRIORITY JOURNAL; SEROTYPE; SOUTHERN BLOTTING; TISSUE DISTRIBUTION; VIRAL GENE DELIVERY SYSTEM;

EID: 0842264039     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-08-2954     Document Type: Article

References (27)

1. Antonarakis SE, Kazazian HH. The molecular basis of hemophilia A in man. Trends Genet. 1998;4:233-237.
2. Kaufman RJ. Expression and structure-function properties of recombinant factor VIII. Med Rev. 1992;4:235-246.
3. Sarkar R, Xiao W, Kazazian HH. A single adeno-associated virus (AAV)-murine factor VIII. J Thromb Haemost. 2003;1:220-226.
4. Chao H, Monahan PE, Liu Y, Samulski RJ, Walsh CE. Sustained and complete phenotypic correction of hemophilia B mice following intramuscular injection of AAV 1 serotype vectors. Mol Ther. 2001;4:217-222.
5. Mingozzi F, Schuttrumpf J, Arruda VR, et al. Improved hepatic gene transfer by using an adeno-associated virus serotype 5. J Virol. 2002;76:10497-10502.
6. Gao GP, Alvira MR, Wang L, Calcedo R, Johnston J, Wilson JM. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci U S A. 2002;99:11884-11859.
7. Cameron C, Notley C, Hoyle S, et al. The canine factor VIII cDNA and 5′ flanking sequence. Thromb Haemost. 1998;79:317-322.
8. Lee J, Greenbaum L, Harber BA, et al. Structure and localization of the IGFBP-1 gene and its expression during liver regeneration. Hepatology. 1994;19:656-665.
9. Wang L, Takabe K, Bidlingmaier SM, Charles R III, Verma IM. Sustained correction of bleeding disorder in hemophilia B mice by gene therapy. Proc Natl Acad Sci U S A. 1999;96:3906-3910.
10. Charles R III, Yang CQ, Bidlingmaier SM, et al. Optimization of the human factor VIII complementary DNA expression plasmid for gene therapy of hemophilia A. Blood Coagul Fibrinolysis. 1997;8: S23-S30.
11. Fisher KJ, Jooss K, Alston J, et al. Recombinant adeno-associated virus for muscle directed gene therapy. Nat Med. 1997;3:306-312.
12. Gao G, Qu G, Burnham MS, et al. Purification of recombinant adeno-associated virus vectors by column chromatography and its performance in vivo. Hum Gene Ther. 2000;11:2079-2091.
13. Bi L, Lawler AM, Antonarakis SE, High KA, Gearhart JD, Kazazian HH Jr. Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A. Nat Genet. 1995;10:119-121.
14. Sambrook J, Maniatis T, Fritsch EF. Molecular Cloning: A Laboratory Manual. 2nd ed. Cold Spring Harbor, NY; Cold Spring Harbor Laboratory; 1998.
15. Nakai H, Thomas CE, Storm TA, et al. A limited number of transducible hepatocytes restricts a wide-range linear vector dose response in recombinant adeno-associated virus-mediated liver transduction. J Virol. 2002;76:11343-11349.
16. Scallan CD, Lillicrap D, Jiang H, et al. Sustained phenotypic correction of canine hemophilia A using an adeno-associated viral vector. Blood. 2003;102:2031-2037.
17. Mah C, Sarkar R, Zolotukhin I, et al. Dual vectors expressing murine factor VIII result in sustained correction of hemophilia A mice. Hum Gene Ther. 2003;14:143-152.
18. Scallan CD, Liu T, Parker AE, et al. Phenotypic correction of a mouse model of hemophilia A using AAV2 vectors encoding the heavy and light chains of FVIII. Blood. 2003;102:3919-3926.
19. Miao CH, Ohashi K, Patijn GA, et al. Inclusion of the hepatic locus control region, an intron, and untranslated region increases and stabilizes hepatic factor IX gene expression in vivo but not in vitro. Mol Ther. 2000;1:522-532.
20. Yonemura H, Sugawara K, Nakashima K, et al. Efficient production of recombinant human factor VIII by co-expression of the heavy and light chains. Protein Eng. 1993;6:669-674.
21. Burton M, Nakai H, Colosi P, Cunningham J, Mitchell R, Couto L. Coexpression of factor VIII heavy and light chain adeno-associated viral vectors produces biologically active protein. Proc Natl Acad Sci U S A. 1999;96:12725-12730.
22. Gnatenko DV, Saenko EL, Jesty J, Cao LX, Hearing P, Bahou WF. Human factor VIII can be packaged and functionally expressed in an adeno-associated virus background: applicability to haemophilia A gene therapy. Br J Haematol. 1999;104:27-36.
23. Yan Z, Zhang Y, Duan D, Engelhardt F. Trans-splicing vectors expand the utility of adeno-associated virus for gene therapy. Proc Natl Acad Sci U S A. 2000;97:6716-6721.
24. Duan D, Yue Y, Yan Z, Engelhardt JF. A new dual-vector approach to enhance recombinant adeno-associated virus-mediated gene expression through intermolecular cis activation. Nat Med. 2000;6:595-598.
25. Chao H, Mao L, Bruce AT, Walsh CE. Sustained expression of human factor VIII in mice using a parvovirus-based vector. Blood. 2000;95:1594-1599.
26. Chao H, Walsh CE. Induction of tolerance to human factor VIII in mice. Blood. 2001;97:3311-3312.
27. Chao H, Sun L, Bruce A, Xiao X, Walsh CE. Expression of human factor VIII by splicing between dimerized AAV vectors. Mol Ther. 2000;5:716-722.